Gadodiamide

Results: 44



#Item
21[removed]Gadobendate Clinical PREA

[removed]Gadobendate Clinical PREA

Add to Reading List

Source URL: www.fda.gov

Language: English
22Pediatric Focused  Safety Review: MultiHance

Pediatric Focused Safety Review: MultiHance

Add to Reading List

Source URL: www.fda.gov

Language: English
23[removed]Gadobutrol Clinical PREA

[removed]Gadobutrol Clinical PREA

Add to Reading List

Source URL: www.fda.gov

Language: English
24Department of Health and Human Services   Public Health Service Food and Drug Administration

Department of Health and Human Services Public Health Service Food and Drug Administration

Add to Reading List

Source URL: www.fda.gov

Language: English
25The recommended dose of Gadavist is 0.1 mL/kg body weight (0.1 mmol/kg), administered as an intravenous bolus injection at a flow rate of approximately 2 mL/second. Flush the intravenous cannula with physiological saline

The recommended dose of Gadavist is 0.1 mL/kg body weight (0.1 mmol/kg), administered as an intravenous bolus injection at a flow rate of approximately 2 mL/second. Flush the intravenous cannula with physiological saline

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-10-18 16:38:58
26Multihance (gadobenate dimeglumine) injection label

Multihance (gadobenate dimeglumine) injection label

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-12-21 13:20:36
27Ablavar (gadofosveset trisodium) solution label

Ablavar (gadofosveset trisodium) solution label

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-12-21 10:25:06
28EU PSUR WORK SHARING SUMMARY ASSESSMENT REPORT DK/H/PSUR[removed]P-RMS:  Invented name of the medicinal

EU PSUR WORK SHARING SUMMARY ASSESSMENT REPORT DK/H/PSUR[removed]P-RMS: Invented name of the medicinal

Add to Reading List

Source URL: www.hma.eu

Language: English - Date: 2014-03-04 09:54:09
29

PDF Document

Add to Reading List

Source URL: www.hma.eu

Language: English - Date: 2014-03-04 10:12:08
30ONC-2R-OSLO  WARING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with: . acute or chronic severe renal insufficiency Cglomerular fi

ONC-2R-OSLO WARING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with: . acute or chronic severe renal insufficiency Cglomerular fi

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2009-03-31 14:43:12